Clinical trial Recruiting at 6 sites Interventional Ages 18 to 70

Space-expanding skull shield used during decompressive surgery for severe stroke

Official title: A Space-expanding Shield in Decompressive Hemicraniectomy for Stroke - a Randomized-controlled Multicenter Phase III Trial

Run by Insel Gruppe AG, University Hospital Bern · NCT06638385 · Data updated 2026-11-12

This trial will try placing a custom space‑expanding skull shield at the time of decompressive hemicraniectomy to let the brain swell safely and reduce the need for a second skull-replacement surgery in adults with malignant middle cerebral artery stroke.

Quick facts

Study typeInterventional
Ages18 Years to 70 Years
SexAll
Enrollment110 (estimated)
SponsorInsel Gruppe AG, University Hospital Bern
Academic / other
Locations6 sites (Aarau and 5 other locations)
StatusRecruiting
StartedJune 1, 2025
Main results expectedDecember 31, 2029
Study endsJune 30, 2030
Registry record updatedJuly 9, 2025
Trial IDNCT06638385 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18 to under 70 with malignant middle cerebral artery infarction who meet European guidelines for decompressive hemicraniectomy and can provide consent via next of kin and an independent physician are eligible.

Probably not a fit

Patients with an immediate hyperacute need for decompression, known allergy to PMMA or gentamicin, pregnancy, prior decompressive or cranioplasty surgery, active cranial or pulmonary infection, or intrinsic coagulopathy are excluded and unlikely to benefit from this protocol.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Malignant middle cerebral artery infarction can cause life-threatening brain swelling that is usually managed by removing a portion of the skull (decompressive hemicraniectomy) followed months later by a second operation to replace the bone (cranioplasty). This study tests a single-stage approach in which a polymethyl‑methacrylate (PMMA) shield is molded and implanted immediately after skull removal to allow swelling while protecting the brain. Participants will receive either decompressive hemicraniectomy plus the space‑expanding shield or decompressive hemicraniectomy followed by standard cranioplasty and will be followed for six months. Enrollment is planned at three Swiss neurosurgery centers between 2025 and 2029.

Why it matters

Potential benefit: If successful, the single-stage shield approach could eliminate a second surgery and reduce complications such as brain exposure, bone resorption, and the syndrome of the trephined.

How similar studies have gone: A prior prospective cohort suggested the intraoperatively molded shield may prevent several cranioplasty-related complications, but randomized and larger comparative data are limited and the single-stage approach remains relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patients with malignant infarction of the middle cerebral artery identified by MRI including diffusion-weighted imaging or CT including perfusion imaging - fulfilling the European guidelines for decompressive hemicraniectomy (DCE) for stroke
* ≥ 18 and \< 70 years of age
* Availability of consent from a next of kin and from the patient represented by an independent physician

Exclusion Criteria:

* Hyperacute need for DCE due to rapid neurological decline
* Contraindications to the use of polymethyl-methacrylate (PMMA), e.g., known hypersensitivity, allergy
* Known gentamicin allergy
* Pregnancy and active breast-feeding
* Patients with a former history of DCE and/or CP
* Active pulmonary or cranial infection
* Known coagulopathy independent of medication

Where it's running

  • Kantonsspital Aarau
    Aarau, Switzerland
    Recruiting
  • Universitätsspital Basel
    Basel, Switzerland
    Recruiting
  • Inselspital Bern, Department of Neurosurgery
    Bern, Switzerland
    Recruiting
  • Luzerner Kantonsspital
    Lucerne, Switzerland
    Recruiting
  • Ente Ospedaliero Cantonale
    Lugano, Switzerland
    Recruiting
  • Kantonsspital St.Gallen
    Sankt Gallen, Switzerland
    Recruiting

Study contacts

  • Principal investigator: Schucht Philippe, MD — Inselspital Bern, Department of Neurosurgery
  • Study coordinator: Philippe Schucht, MD
  • Email: philippe.schucht@insel.ch
  • Phone: +41316322409

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.